Search Results
Your search for ,are matches 21903 pages
Showing 8251 - 8300AACR 2020: Study Finds Vape Shops Are Mostly Concentrated in Low-Resource, Minority Communities
An analysis investigating the socioecologic context of tobacco and vape shops in Los Angeles has found that vape shops are more likely to be concentrated in low-resource communities. The communities also tended to have higher concentrations of minority residents and fewer tobacco and vaping sales...
AACR 2020: Continuous vs Intermittent Dabrafenib/Trametinib Dosing in Patients With BRAF-Mutated Melanoma
A randomized clinical trial offers evidence that a combination of two targeted melanoma drugs, when given continuously, improves progression-free survival when compared with intermittent treatment, according to study results presented by Algazi et al at the American Association for Cancer Research...
ASCO Shares New Clinical Trial Data, Initiatives, and Path Forward for Post–COVID-19 Cancer Care Delivery System
ASCO (the Society) and its affiliate organization the Association for Clinical Oncology (the Association) recently announced the results of a survey that tracked the initial impact of the COVID-19 pandemic on cancer clinical trials, highlighted a new research initiative to address the data gap on...
Hypercoagulability in Critically Ill Patients With COVID-19: Where Do We Stand?
“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” ―Hippocrates The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Connors...
AACR 2020: Final Overall Survival Results From the Phase III EMBRACA Trial
New data from the phase III EMBRACA trial showed the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib did not produce a statistically significant overall survival benefit for patients with locally advanced or metastatic HER2-negative germline BRCA-mutated breast cancer. Most patients...
ASCO, Conquer Cancer Honor Leaders in Cancer Care With 2020 Special Awards
ASCO and Conquer Cancer, the ASCO Foundation®, are proud to recognize the winners of ASCO’s 2020 Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. David A. Karnofsky Memorial Award...
Isatuximab-irfc for Previously Treated Multiple Myeloma
On March 2, 2020, the CD-38-directed cytolytic antibody isatuximab-irfc (Sarclisa) was approved for use in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.1,2...
Robert L. Coleman, MD, Named Chief Scientific Officer for the US Oncology Network
On March 31, 2020, the US Oncology Network (The Network) named cancer researcher Robert L. Coleman, MD, FACOG, FACS, as its new Chief Scientific Officer. In this role, Dr. Coleman will be the senior-most clinician scientist on The US Oncology Network leadership. Dr. Coleman, who most recently...
NCI Awards $14.5 Million Grant for Immunotherapy Research
A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center, has earned a 5-year, $14.5 million award from the National Cancer Institute (NCI) to expand a promising immunotherapy platform. Funded through the NCI’s Program Project Grant, this 5-year grant will fund five...
Virtual Appointments Help Patients With Cancer Continue Care During COVID-19 Health Crisis
Texas Oncology recently announced a major expansion of its telemedicine services to allow patients to schedule virtual visits with more than 400 physicians and 150 advanced practice providers throughout the statewide cancer care practice. Through this expanded approach, launched earlier this month, ...
FDA Accelerates Development of Novel Therapies for COVID-19
The U.S. Food and Drug Administration (FDA) has implemented a program to expedite the development of potentially safe and effective life-saving treatments. The program, known as the Coronavirus Treatment Acceleration Program (CTAP), is using every tool at the agency’s disposal to bring new...
Adapting Adjuvant Endocrine Therapy by Patient Age and Risk
The individualization and optimization of adjuvant endocrine therapy for breast cancer are important and not always simple. Guidance on this issue was offered at the 2020 Miami Breast Cancer Conference by Joyce O’Shaughnessy, MD, the Celebrating Woman Chair in Breast Cancer Research at Baylor...
Radon Exposure: A Leading Environmental Cause of Cancer Mortality in the United States
The Environmental Protection Agency (EPA) has concluded that about 21,000 people die each year of lung cancer related to radon gas exposure, making it the second leading cause of lung cancer death in the United States. Although the EPA and various other organizations, including the National Radon ...
PD-1 Inhibition in Mismatch Repair–Deficient/Microsatellite Instability–High Cancers Other Than Colorectal Cancer
Mismatch repair (MMR)-deficiency and consequently high DNA microsatellite instability (MSI-H) are associated with high tumor mutational burden. A high mutational load increases the potential number of neoantigens that can be presented by the tumor cell and recognized by host lymphocytes. Detection...
Actively Recruiting Clinical Trials Studying Multiple Myeloma
This Clinical Trials Resource Guide lists six actively recruiting clinical trials that focus on treating multiple myeloma. These studies, ranging from phase I to phase III, are evaluating the safety and efficacy of vaccines, cytotoxic T lymphocytes, and drug treatment regimens. Some studies center ...
Gut Bacterial Diversity: A Marker or Driver of Outcomes After Hematopoietic Cell Transplantation?
Previous single-center studies have linked the gut microbiota (via stool sample analysis) to outcomes after hematopoietic cell transplantation (HCT), such as overall mortality, transplant-related mortality, graft-vs-host disease, and graft-vs-host–related mortality.1-4 Although intriguing, these...
Selected ASH Abstracts on Novel Treatments for Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for patients with non-Hodgkin lymphomas (NHLs). For full...
How CRISPR-Cas9 Gene Editing May Improve the Effectiveness of Cellular Therapeutics in Patients With Cancer
The results from the first in-human phase I clinical trial in the United States evaluating CRISPR-Cas9–edited T cells in patients with advanced cancer has shown that the therapy is both feasible and safe, representing a big step forward in the potential of using gene editing to boost the natural...
CheckMate 142 Updated Analysis: First-Line Nivolumab Plus Low-Dose Ipilimumab in MSI-H/dMMR Metastatic Colorectal Cancer
As a first-line regimen for patients with metastatic colorectal tumors that are microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR), the combination of nivolumab and low-dose ipilimumab yielded an objective response rate of 64%, a complete response rate of 9%, and a disease...
ASCENT Study Halted: Efficacy Shown Across Multiple Study Endpoints in Triple-Negative Breast Cancer
The phase III confirmatory ASCENT study of the antibody drug-conjugate sacituzumab govitecan will be stopped based on efficacy across multiple study endpoints following unanimous recommendation from the independent data safety monitoring committee, according to a news release issued earlier this...
Beyond CDK4/6 Inhibitors: What Subsequent Treatment Is Best?
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have changed the natural history of hormone receptor–positive metastatic breast cancer. While median progression-free survival on these drugs is approximately 27 months, the disease eventually progresses and clinicians must choose a subsequent ...
More Antibody-Drug Conjugates on the Horizon for Breast Cancer
Novel antibody-drug conjugates that target actionable cell-surface markers in metastatic breast cancer will soon expand the utility of the class that already includes ado-trastuzumab emtansine (T-DM1), according to two speakers at the 2020 Miami Breast Cancer Conference. These new agents were...
Do HIV Positivity and Autoimmune Disease Preclude Treatment With Checkpoint Inhibitors?
Can patients with cancer and preexisting autoimmune disorders safely benefit from immunotherapy? The answer has been unclear, with only retrospective studies and anecdotal reports guiding oncologists. This subpopulation of patients has largely been excluded from clinical trials out of concerns over ...
What’s the Current Status of Neoadjuvant Immunotherapy?
For several tumor types, can the successes achieved with immunotherapy in the metastatic and adjuvant settings be replicated in the neoadjuvant setting? An explosion in clinical trials—with more than 300 listed on ClinicalTrials.gov—point to “yes.” “The neoadjuvant use of immunotherapy is of great ...
Expert Point of View: Dana E. Rathkopf, MD
Study discussant Dana E. Rathkopf, MD, Director of Clinical Research, Prostate Cancer, at Memorial Sloan Kettering Cancer Center, New York, began her presentation by noting that the “complicated” landscape of metastatic prostate cancer can be approached like a chess game. She used a chess analogy...
Free Practice Resource: Cancer.Net Patient Referral Cards From ASCO
Patients and caregivers are always looking for trusted online information on cancer topics. Display these free referral cards in your practice to encourage your patients to visit ASCO’s patient information website, Cancer.Net, where they will find authoritative, oncologist-approved information...
Better Mental Health Screening Needed for Survivors of Head and Neck Cancer
The threat posed by head and neck cancer extends well beyond the physical disease, according to research presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium.1,2 The pair of studies underscored the high costs of survivorship, including elevated rates of chronic pain, substance...
Conquer Cancer Researchers Remember Jane C. Wright, MD, FASCO
It’s 1964 in Chicago. Seven forward-thinking oncologists gather to brainstorm what will become the American Society of Clinical Oncology (ASCO). Among the group is Jane C. Wright, MD, FASCO, the only woman and African American among ASCO’s founders. It’s time for the 2011 ASCO Annual Meeting in...
FDA’s Draft Guidance Will Improve Evidence Base for Older Adults With Cancer
ASCO commends the U.S. Food and Drug Administration (FDA) for releasing draft guidance that encourages inclusion of older adults in clinical trials of drugs for the treatment of cancer. The guidance emphasizes the importance of including adults aged 75 or older in clinical trials to better enable...
Expert Point of View: Charu Aggarwal, MD, MPH
Charu Aggarwal, MD, MPH, Leslye M. Heisler Assistant Professor for Lung Cancer Excellence at the Perelman Center for Advanced Medicine, University of Pennsylvania, underscored the paucity of treatment options for metastatic head and neck squamous cell carcinoma. “Even though pembrolizumab is...
Pembrolizumab Plus Cetuximab Shows Antitumor Activity in Squamous Cell Head and Neck Cancer
The first trial to evaluate anti–programmed cell death protein 1 (PD-1) blockade combined with epidermal growth factor receptor (EGFR) inhibition in head and neck squamous cell carcinoma demonstrates promising activity of the drug combination in patients with platinum-refractory or -ineligible...
It’s T Time for Peripheral T-Cell Lymphoma, a Much-Neglected Disease
The lymphomas are an incredibly complex assemblage of neoplastic diseases. They are not one disease, and, at least based on the World Health Organization (WHO) Classification of Tumors published in 2017, they represent a collection of approximately 80 different malignancies, a number that will...
EXPECT INTEREST AND QUESTIONS ABOUT STATINS AND METFORMIN
A study showing that statins used alone or in combination with metformin was associated with reduced prostate cancer mortality and all-cause mortality among men with high-risk prostate cancer may raise more questions about these already commonly used drugs.1 “Metformin is the first-line therapy for ...
Statins With or Without Metformin Are Associated With Increased Survival in Patients With High‑Risk Prostate Cancer
A population-based retrospective cohort study involving 12,700 patients found that men with high-risk prostate cancer who took a statin alone or in combination with metformin had reduced all-cause and prostate cancer–specific mortality. The associations between the medications and reduced...
A Clinical Trial Saved My Life
In the fall of 2009, I began experiencing some abdominal discomfort, pain in my right shoulder, and severe fatigue that were easily explained away as the result of gallstones and by my career as a paramedic. I had many of the risk factors for gallbladder disease, and both my mother and sister...
Nivolumab/Ipilimumab in Patients With Sorafenib-Pretreated Hepatocellular Carcinoma
On March 10, 2020, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was granted accelerated approval for treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.1-3 Supporting Efficacy Data The approval was based on findings in a cohort...
Inoperable Carcinoma of the Breast
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The X-Ray Era: 1901–1915 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Dr. Burns and The Burns Archive. To view ...
Chemotherapy and the Sweat Lodge
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Unnecessary Barrier to Blood Donation for British Nationals?
I read with great interest Jo Cavallo’s article “Maintaining Blood Donations During the COVID-19 Pandemic”. My wife and I have been British residents in the United States for over 6 years and are frustrated that we cannot donate blood, especially during this raging global COVID-19 pandemic, when...
NIH Launches $1 Million Competition to Target Disease Diagnostics
The National Institutes of Health (NIH) has launched the $1 million Technology Accelerator Challenge to spur the design and development of noninvasive, handheld, digital technologies to detect, diagnose, and guide therapies for diseases with high global and public health impact. The challenge is...
Joseph C. Alvarnas, MD, on the Increased Risk of Side Effects for Patients With Cancer and COVID-19
Joseph C. Alvarnas, MD, of the City of Hope National Medical Center, discusses the patients with cancer who are at an increased risk for developing serious complications from COVID-19, including those receiving bone marrow or stem cell transplants and CAR-T cell therapy, and what they can do to...
Helping Patients to Feel Informed About Goals and Adverse Effects of Cancer Treatments
How confident should oncologists be that their patients feel adequately informed about the adverse effects of their cancer treatment? A recent study by Shaverdian et al,1 reported in the Journal of Oncology Practice and reviewed in this issue of The ASCO Post, found that 18% of 403 patients felt...
Survey of Patients’ Experience With Radiation Therapy for Cancer Finds Some Gaps in Expectation vs Reality
In a study reported in JCO Oncology Practice, Narek Shaverdian, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that most patients undergoing radiation therapy for cancer reported that anticipated adverse effects did not occur or were no worse than expected.1 However, ...
Gut Microbiota Emerging as Key Player in Response to Immunotherapy
The microbiome—and the foods that feed it—is emerging as an important determinant of a patient’s response to immunotherapy. Much of the research in this area comes from The University of Texas MD Anderson Cancer Center, as described at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium by...
Intermittent Dawn-to-Sunset Fasting and Anticancer Serum Proteome
In a small study published in the Journal of Proteomics, Ayse Leyla Mindikoglu, MD, MPH, and colleagues found that dawn-to-sunset fasting was associated with proteins that were protective against cancer as well as obesity, diabetes, metabolic syndrome, inflammation, and some neurologic disorders...
After Training Across Three Continents, a Hematologist Leads the Wisconsin Hematology/Oncology Division
In this edition of Living a Full Life, guest editor Jame Abraham, MD, FACP, spoke with hematologist Parameswaran Hari, MD, MRCP, Chief of the Division of Hematology and Oncology at the Medical College of Wisconsin, Milwaukee. In addition, Dr. Hari holds the Armand J. Quick/William F. Stapp Chair...
Budwig Diet
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on the Budwig...
Vitamin D and Lymphoma: An Apparent Benefit, but Further Study Required
Vitamin D is a steroid-like hormone involved primarily in human calcium homeostasis. Obtained through sun exposure as well as food and dietary supplements,1 vitamin D in humans is metabolized in the liver and kidneys to its active form, 1,25-dihydroxyvitamin D (1,25[OH]2D).2 Other cell types,...
ACS Releases New Guidance to Help Health-Care Facilities Prepare for Resuming Elective Surgery Past COVID-19 Peak
The American College of Surgeons (ACS) has released a new surgical resource document, “Local Resumption of Elective Surgery Guidance,” as a guide for health-care facilities preparing to resume elective surgery once COVID-19 has peaked in their area. Health-care facilities have been allocating...
David A. Tuveson, MD, PhD, FAACR, Named AACR President-Elect for 2020–2021
The members of the American Association for Cancer Research (AACR) have elected David A. Tuveson, MD, PhD, FAACR, as their President-Elect for 2020–2021. He will officially become President-Elect on April 29, 2020, during the AACR’s Business Meeting of Members. He will assume the presidency in...
